Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.